ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.
ADIENNE aims to develop a range of product candidates for orphan diseases, for which existing treatment options are limited, the patient population is small, and the clinical need for therapies is high.
The Group is focused on orphan drug development for the treatment of various haematological and immunological diseases, in which the group has high expertise and proven in-house capabilities from discovery to commercialization.
In addition, the Group has its own Good Manufacturing Practice (“GMP”)-approved manufacturing facility, which is authorized for the production of biotechnological sterile products for clinical trials and commercial use.
Dr. Antonio Francesco Di Naro, Chairman and President, started in 2004 to build the Group, which currently has 60 employees.
The Company’s headquarters are based in Lugano (Switzerland), its manufacturing site is based in Caponago (Italy) and a subsidiary is located in Barcelona (Spain ).